Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A legfontosabb adatok
- Hol
- Bangkok, Mueng és Songkhla (Thaiföld)Mind a 4 helyszín megnézése
- Fázis
- 2/3. fázis
Helyszínek itt: Thaiföld
- BangkokHospital not named in the registryContact: Site 0265Toborzás még nem indult
- BangkokHospital not named in the registryContact: Site 0264Toborzás még nem indult
- Mueng, Changwat Khon KaenHospital not named in the registryContact: Site 0272Toborzás még nem indult
- SongkhlaHospital not named in the registryContact: Site 0266Toborzás még nem indult
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Bristol-Myers Squibb
- Azonosító
- NCT07100080
- A regiszteradat frissítve
- 2026. november 12.
- Eredeti leírás
A study of Izalontamab Brengitecan (BMS-986507) versus platinum-based chemotherapy with or without Amivantamab for EGFR-mutated non-small cell lung cancer after failure of EGFR TKI therapyA teljes eredeti leírásKevesebb
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
A study of Izalontamab Brengitecan (BMS-986507) versus platinum-based chemotherapy with or without Amivantamab for EGFR-mutated non-small cell lung cancer after failure of EGFR TKI therapy
Bevonási feltételek: Non-squamous NSCLC, not amenable to treatment in curative intent; Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation); Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting; Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin) in combination with pemetrexed with or without amivantamab.
Kizáró feltételek: Poorly controlled systemic medical conditions; Inadequate organ function and/or bone marrow reserve; Leptomeningeal metastases or spinal cord compression; Other protocol-defined inclusion/exclusion criteria apply.